The trend towards decreased IL-17 secretion in an increasing proportion of patients on higher pharmacological doses of vitamin D is in agreement with earlier studies which demonstrated that high dose vitamin D decreases Th-17 cell activity in animal models of MS [31,32] as well as in PwMS [33]. Here, IL17A is linked to myeloid sarcoma.